Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- ILa | -.--% | -0.67% | -16.62% |
08/05 | Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
14/03 | Top Premarket Gainers | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Newman
FOU | Founder | 68 | 24/21/24 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 03/21/03 |
Nir Sassi
DFI | Director of Finance/CFO | 48 | 01/21/01 |
Roger Waltzman
CTO | Chief Tech/Sci/R&D Officer | 56 | 07/23/07 |
Walt Linscott
COO | Chief Operating Officer | 63 | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
William Hayes
BRD | Director/Board Member | 58 | 03/21/03 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 03/21/03 |
Robert Martell
BRD | Director/Board Member | 61 | 13/23/13 |
Hila Karah
BRD | Director/Board Member | 55 | 01/21/01 |
Michael Newman
FOU | Founder | 68 | 24/21/24 |
Roger Pomerantz
CHM | Chairman | 67 | 01/21/01 |
Director/Board Member | 71 | 01/21/01 | |
Mark Gilbert
BRD | Director/Board Member | 63 | 01/21/01 |
Company contact information
Sector
- Stock Market
- Equities
- INDP Stock
- NTEC Stock
- Company Intec Pharma Ltd